Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CYPB - Cypress BioScience -- Ignore unavailable to you. Want to Upgrade?

To: Ie Coan Bie who wrote (61)	1/23/1998 10:09:00 AM
From: Ben Geh	Read Replies (1) \| Respond to of 586

Here's what I like about CYPB: <<<<<<<<<<---------------------------------------------------->>>>>> SAN DIEGO--(BW HealthWire)--Jan. 12, 1998--Cypress Bioscience, Inc. (NASDAQ:CYPB - news) announced that its Phase III pivotal trial...... We will shortly announce a time for a conference call during which we will be able to disclose the results, along with our timetable for filing for regulatory approval and our commercialization plans,'' said Debby Jo Blank, M.D., President and COO of Cypress Bioscience..... A recently acquired product, Cyplex (TM), (infusible Platelet Membranes), is positioned to become an alternative for traditional platelet infusions, an estimated $1.5 billion market worldwide. <<<<<<<--------------------------------------------------------->>>>> Now somebody has reported on this board that the conference call had been scheduled on Tuesday 27 at 4pm Market for RA is $2 billion. I am keeping this for the long term.